3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Myelodysplastic Syndromes
4
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neuroblastoma
3
Lymphoma, Large B-Cell, Diffuse
3
Recurrence
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Hepatoblastoma
2
Glioblastoma
2
Breast Neoplasms
2
Brain Neoplasms
2
Anemia, Refractory, with Excess of Blasts
2
Wilms Tumor
1
Uveal Melanoma
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Primary Malignant Peripheral Nerve Sheath Tumors
1
Ototoxicity
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
pembrolizumab
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Cisplatin
4
Carboplatin
4
Biopsy
4
trastuzumab deruxtecan
3
Trastuzumab
3
Platinum
3
Goserelin
3
Docetaxel
3
sacituzumab govitecan
2
pertuzumab
2
entrectinib
2
darolutamide
2
Radiotherapy, Intensity-Modulated
2
Leuprolide
2
Ado-Trastuzumab Emtansine
2
1,2-diaminocyclohexaneplatinum II citrate
2
zanidatamab
1
trastuzumab biosimilar HLX02
1
spartalizumab
1
selinexor
1
pyrotinib
1
luprolide acetate gel depot
1
lenvatinib
1
larotrectinib
1
enfortumab vedotin
1
dehydroftorafur
1
ceralasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Vorinostat
×
1 year
×
Clear all
No trials found.